Clinical Trial: A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.

U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07340424) titled 'A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.' on Jan. 06.

Brief Summary: This study is a prospective, single-center, single-arm, open-label research. It evaluates the safety and tolerability of 225Ac-TR2205 in patients with triple-negative breast cancer (TNBC), and assesses its radiation dosimetry and initial efficacy.

Study Start Date: May 22, 2025

Study Type: INTERVENTIONAL

Condition: Advanced Metastatic Triple-negative Breast Cancer (mTNBC)

Intervention: DRUG: 225Ac-TR2205 Injection

Patient...